Botulinum toxin type A treatment of four cases of Wilson disease with lower limb dystonia: A prospective study.

Botulinum toxin type A (BoNT-A) has been recommended in various neurological disorders as a useful tool for alleviating dystonia. In Wilson disease (WD) patients with dystonia, BoNT-A injection can be used as a treatment modality when conventional treatment is ineffective for alleviating symptoms. The purpose of this study was to thoroughly evaluate the efficacy of BoNT-A injection in treating WD complicated by lower extremity dystonia. The efficacy of these injections was assessed by clinical scales, surface electromyography (EMG), and gait analysis. A comparative analysis of all gait parameters, EMG parameters, and clinical scales revealed a significant increase in velocity, decrease in integrated EMG (iEMG), and improvement in modified Ashworth scale (MAS), Burke Fahn Marsden (BFM), and activities of daily living (ADL) scores (all P < 0.05). Overall, our findings indicated that BoNT-A injection led to marked relief of symptoms in patients with WD with lower extremity dystonia. [Display omitted] • Single-blind, pre-and post-intervention study were initially performed in Wilson disease patients with lower limb dystonia. • Botulinum toxin type A injection improves the muscle tone, as evident by the decrease in integrated electromyogram. • Botulinum toxin type A injection improves walking function, as evident by the increase in velocity. • Botulinum toxin type A injection alleviates the symptoms of lower limb dystonia in Wilson disease patients. [ABSTRACT FROM AUTHOR]